US006551586B1

(12) **United States Patent**
Davidson et al.

(10) **Patent No.: US 6,551,586 B1**
(45) **Date of Patent: Apr. 22, 2003**

(54) **MALARIA VACCINE BASED UPON THE ADDITION OF A MSA1 PEPTIDE**

(75) Inventors: **Eugene A. Davidson**, Washington, DC (US); **Shutong Yang**, Washington, DC (US)

(73) Assignee: **Georgetown University**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/117,415**

(22) Filed: **Nov. 27, 1998**

Related U.S. Application Data

(63) Continuation-in-part of application No. 08/593,006, filed on Jan. 29, 1996, now abandoned.
(60) Provisional application No. PCT/US97/01395, filed on Jan. 29, 1996.

(51) **Int. Cl.**[7] **A01N 63/00**
(52) **U.S. Cl.** **424/93.2**; 514/44; 435/320.1; 435/69.1; 435/325; 435/455
(58) **Field of Search** 514/44; 536/23.1, 536/23.4, 24.1; 435/69.1, 320.1, 325, 455; 424/93.1, 93.2, 184.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,032,520 A		7/1991	Binns et al.	435/325
5,225,534 A		7/1993	Certa	530/350
5,541,087 A	*	7/1996	Lo et al.	435/697
5,585,268 A		12/1996	Knapp et al.	435/252.3
5,756,101 A	*	5/1998	Paoletti et al.	424/199.1
5,766,597 A	*	6/1998	Paoletti et al.	424/199.1
5,876,964 A	*	3/1999	Croteau et al.	435/69.1
5,948,647 A	*	9/1999	Ring	435/69.6

FOREIGN PATENT DOCUMENTS

WO	WO94/21680	9/1994
WO	WO 94/28930	12/1994
WO	WO 96/34105	10/1996
WO	WO 97/30159	8/1997

OTHER PUBLICATIONS

McCluskie et al., Molecular Medicine, 5, 287–300, 1999.*
Stoute et al., BioDrugs, 10/2, pp. 123–136, 1998.*
Database Biotechds, AN: 1996–13489, Hestrom et al., abstract, Nov. 1995.*
Murphy et al., Parasitology, 11, Pt 2, pp. 177–183, 1990.*
Longacre et al., Mol. Biochem. Parasitol., 64, 2, 191–205, 1994.*
Hui et al. Infection and Immunity 61:3403 (1993).
Gierasch Perspectives in Biochemistry 28:923 (1989).
von Heijne Subcellular Biochemistry 22:1 (1994).
Englund Annu. Review Biochem. 62: 121 (1993).
Arita Nature 279:293 (1979).
Mackett et al. J. Gen Virol. 67:2067 (1986).
Houard et al. J Gen. Virol. 76:421 (1995).
Fujii et al. J. Gen Virol 76:1339 (1995).
Rodrigues et al. J Immunol. 153:4636 (1994).
Earl et al. Current Protocols in Molecular Biology Units 16.1–16.2 (1993).
Smith et al. Gene 25:21 (1983).
Chakrabarti et al. Nature 320: 535 (1986).
Hu et al. Nature 320:537 (1986).
Ball et al: Proc. Natl. Acad. Sci 83:246 (1986).
de La Salle et al. Nature 316:268 (1985).
Langford et al. Mol. Cell Biol. 6:3191 (1986).
Blackman et al. Mol.Biochem. Parastilol. 49:29 (1991).
Perrin et al. J. Exp. Med 160:441 (1984).
Siddiqui et al. Proc. Natl. Acad. Sci. USA 84:3014 (1987).
Perrin et al. Immunol. Rev. 61: 245 (1982).
Holder et al. Parasitology 94. 199 (1987).
McBride et al. Mol.Biochem. Parastilol. 23:71 (1987).
Blackman et al. Mol.Biochem. Parastilol. 49:35 (1991).
Fox et al. Infect. Imm. 61:2309 (1993).
Holder et al. Parasite Immunol. 10:607 (1988).
Günzburg Molecular Medicine Today vol. 12, 9:410–417, 1995.
Coghlan New Scientist, vol. 148 pp. 14–15, 1995.
Crystal Science 270: 404–407 (1995).
Robert Whalen Emerging Infectious Diseases 2:168–175.
Etlinger Immunology Today 1312:52–55 (1992).
Cryz Vaccine 14: 683–687 (1996).
Kaslow D. C. et al. "Expression and Antigenicity of Plasmodium Falciparum Major Merozoite Surface Protein (MSP119) Variants Secreted From Saccharomyes Cerevisiae" *Molecular aned Biochemical Parasitology*, 63(2): 283–289, 1994.
Sandhu J. S. and Kennedy J F. "Expression of the Merozoite Surface Protein GP195 in Vaccinia Virus" *Vaccine*, 12(1): 56–64, 1994.
Kumar S. et al. "Immunogencity and In Vivo Efficacy of Recombinant Plasmodium Falciparum Merozoite Surface Protein–1 in Aotus Monkeys" *Molecular Medicine*, 1(3): 325–332, 1995.

* cited by examiner

Primary Examiner—Dave Trong Nguyen
(74) *Attorney, Agent, or Firm*—Henry D. Coleman; Coleman Sudol Sapone P.C.

(57) **ABSTRACT**

The present invention relates to an expression vector which expresses a malaria MSA1 peptide in combination with a signal peptide and anchor peptide in a host animal. The MSA1 peptide is combined with a signal peptide and anchor peptide for expression. Chimeric peptides being expressed with both signal peptides and anchor peptides were the most effective in eliciting an immunogenic response from a vaccinated host.

8 Claims, 13 Drawing Sheets